Neumora Therapeutics (NMRA) Change in Account Payables (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Change in Account Payables of $1.7 million for Q1 2026, up 174.41% year-over-year from $611488.4 in Q1 2025, and down 40.71% quarter-over-quarter from $2.8 million in Q4 2025.
Neumora Therapeutics (NMRA) Change in Account Payables (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Change in Account Payables history runs 5 years deep, the most recent figure standing at $1.7 million for Q1 2026.
- In Q1 2026, Change in Account Payables rose 174.41% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $4.0 million (up 845.62% YoY), while the FY2025 annual figure was $71000.0, down 97.53% from the prior year.
- Change in Account Payables for Q1 2026 stood at $1.7 million, down from $2.8 million in the prior quarter.
- The five-year high for Change in Account Payables was $7.0 million in Q2 2023, with the low at -$6.0 million in Q1 2023.
- The 5-year median for Change in Account Payables is -$252000.0 (2025), against an average of $66571.4.
- The sharpest annual moves came in 2024 and 2025: Change in Account Payables surged 1542.16% in 2024, then tumbled 295.24% in 2025.
- Neumora Therapeutics' Change in Account Payables stood at -$3.1 million in 2022, then surged by 38.5% to -$1.9 million in 2023, then slumped by 51.52% to -$2.9 million in 2024, then surged by 197.69% to $2.8 million in 2025, then plunged by 40.71% to $1.7 million in 2026.
- Business Quant data shows NMRA's Change in Account Payables at $1.7 million in Q1 2026, $2.8 million in Q4 2025, and -$96000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 1.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.68 Mn |
| Mar 31, 2026 | 1.68 Mn |
| Dec 31, 2025 | 2.83 Mn |
| Dec 31, 2025 | 2.83 Mn |
| Sep 30, 2025 | -96,000.00 |
| Sep 30, 2025 | -96,000.00 |
| Jun 30, 2025 | -408,000.00 |
| Jun 30, 2025 | -408,000.00 |
| Mar 31, 2025 | -2.26 Mn |
| Mar 31, 2025 | -2.26 Mn |
| Dec 31, 2024 | -2.90 Mn |
| Dec 31, 2024 | -2.90 Mn |
| Sep 30, 2024 | 5.03 Mn |
| Sep 30, 2024 | 5.03 Mn |
| Jun 30, 2024 | -410,000.00 |
| Jun 30, 2024 | -410,000.00 |
| Mar 31, 2024 | 1.16 Mn |
| Mar 31, 2024 | 1.16 Mn |
| Dec 31, 2023 | -1.91 Mn |
| Dec 31, 2023 | -1.91 Mn |